awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q42392542-81B01557-150A-44A5-8125-2FE77039B803
Q42392542-81B01557-150A-44A5-8125-2FE77039B803
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42392542-81B01557-150A-44A5-8125-2FE77039B803
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
P1476
Q42392542-81B01557-150A-44A5-8125-2FE77039B803
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42392542-81B01557-150A-44A5-8125-2FE77039B803
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
83ed90b7b365613b55d524a095de385201d5e842
P1476
Comment on 'costs of managing
......
-α2a compared with sunitinib'.
@en